MS INBRE UM: PHARMOCOGENOMICS FACILITY

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. During the 2005-06 funding period the Pharmacogenomics/Toxicogenomic facility at the University of Mississippi has focused specifically on providing research infrastructure and support to the MFGN fellows as well as other researchers around the state in need of help getting started with fundable biomedical research programs. This has included visits by Fellows to this campus to encourage discussion and collaboration with respect to their research endeavors. We have recently hired a research scientist to oversee the Pharmacogenomics/Toxicogenomic facility who will be designing methods workshops for both in-person presentations and web access. ? The cadre of researchers associated with the Pharmacogenomics/Toxicogenomic facility at University of Mississippi provide one of the largest regional institutions of successfully NIH-funded biomedical researchers. This includes funded research projects from the following institutes: the National Center for Infectious Diseases (NCID), the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute on Drug Abuse (NIDA), the National Cancer Institute (NCI), the National Center for Complementary & Alternative Medicine (NCCAM), the Fogarty International Center, and the National Institute of Environmental Health Sciences, which provides a wide base of knowledge and skills in that are being offered to help new investigators throughout the state. ? Expertise, equipment and infrastructure provided via the Pharmacogenomics/Toxicogenomic facility at University of Mississippi includes all aspects of drug discovery and development, automated DNA and oligonucleotide sequencing capabilities, development of drug screening technologies (antimicrobial, anticancer, etc.), RT-PCR technologies, Affymetrix microarray technology, separations technologies (LCMS, HPLC, LPLC, etc.), spectroscopy technologies (1D & 2D-NMR, ELS, UV-VIS, etc.) fermentation and cell biology technologies, environmental toxicology, etc.